Xiaoyan Lin

928 total citations · 1 hit paper
36 papers, 518 citations indexed

About

Xiaoyan Lin is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiaoyan Lin has authored 36 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 12 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaoyan Lin's work include Cancer Cells and Metastasis (4 papers), Peptidase Inhibition and Analysis (3 papers) and HER2/EGFR in Cancer Research (3 papers). Xiaoyan Lin is often cited by papers focused on Cancer Cells and Metastasis (4 papers), Peptidase Inhibition and Analysis (3 papers) and HER2/EGFR in Cancer Research (3 papers). Xiaoyan Lin collaborates with scholars based in China, United States and Japan. Xiaoyan Lin's co-authors include Minghong Wang, Fengfeng Cai, Ewelina Biskup, Guanghui Wang, Wei Dong, Lingling Guo, Hongchang Shen, Xueru Mu, Zhenxiang Li and Hong Chang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Xiaoyan Lin

34 papers receiving 516 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer

2025 17 citations Yinghao Chen, Cheng‐Yu Liao et al. Drug Resistance Updates profile →

Peers

Countries citing papers authored by Xiaoyan Lin

Since Specialization

Citations

This map shows the geographic impact of Xiaoyan Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoyan Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoyan Lin more than expected).

Fields of papers citing papers by Xiaoyan Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoyan Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoyan Lin. The network helps show where Xiaoyan Lin may publish in the future.

Co-authorship network of co-authors of Xiaoyan Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoyan Lin. A scholar is included among the top collaborators of Xiaoyan Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoyan Lin. Xiaoyan Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis 2025 ·Cancer Research ·Yongding Wu, Xiaoxiao Huang, Haoxiang Zhang, Yu Pan, (unknown), (unknown), (unknown), Xiaoyan Lin, (unknown), (unknown), (unknown), Hong-Yi Lin, (unknown), Zuwei Wang, (unknown), (unknown), Cheng‐Yu Liao, Shi Chen	1
2	Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer breakdown → 2025 ·Drug Resistance Updates ·(unknown), (unknown), Yinghao Chen, (unknown), (unknown), Cheng‐Yu Liao, Xiaoxiao Huang, (unknown), Yongding Wu, Zhiyuan Li, (unknown), Xiaoyan Lin, (unknown), Qiaowei Li, Zuwei Wang, Shi Chen	17
3	An effective fluorescence strategy based on xanthine oxidase catalysis and the carbon dots’ specific response to ·OH for aminophylline pharmacokinetic studies 2025 ·Materials Today Bio ·Chenfang Miao, Changwen Zhang, Ying Zheng, Xiaoyan Lin, (unknown), (unknown), Sitong Lu, Zhengjun Huang, Jianyong Huang, Yanjie Zheng, Shaohuang Weng	1
4	Dextran guanidinylated carbon dots with antibacterial and immunomodulatory activities as eye drops for the topical treatment of MRSA-induced infectious keratitis 2025 ·Acta Biomaterialia ·Menghan Zhang, (unknown), Chenfang Miao, Shin‐Yu Lin, Ying Zheng, Xiaoyan Lin, Wang Yao, Xinhua Lin, (unknown), Shaohuang Weng	6
5	Development of a novel prognostic model for mantle cell lymphoma based on quantitative detection of CD3 by quantitative dot blot 2025 ·Frontiers in Oncology ·Ning Zhu, Yunjun Wang, Jiajia Hu, Xiaoyan Lin, Cuijuan Zhang, (unknown), Guohua Yu	0
6	EXO1 is a key gene for lung-resident memory T cells and has diagnostic and predictive values for lung adenocarcinoma 2025 ·Scientific Reports ·Zhuoqi Li, Xiaoyan Lin, Yang Yang, (unknown), Lu Zhang, (unknown), Wen Xiao, Zhigang Wei, Yuan Tian	1
7	Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study 2024 ·Frontiers in Cell and Developmental Biology ·Weiwei Huang, Chenxi Wang, Lili Wang, (unknown), Qi Chen, Zhijian Huang, Jian Liu, Xiaoyan Lin, Fan Wu, Xinhua Chen, (unknown), Hong Yi, (unknown), Jieyu Li, Chuanzhong Huang	0
8	Reconceptualizing the clinicopathological features, locoregional therapy and prognostic factors of occult breast cancer in the era of molecular subtyping 2022 ·Women & Health ·(unknown), Li Yang, (unknown), Xiaoyan Lin, Jie Wang, Rongrong Cui, (unknown)	1
9	Adenosquamous carcinoma of the breast: a population-based study 2021 ·Breast Cancer ·(unknown), (unknown), Juan Liu, Xiaoyan Lin, (unknown), (unknown), Yun Fu, (unknown), Zhigang Zhuang	6
10	Detection Methods and Clinical Applications of Circulating Tumor Cells in Breast Cancer 2021 ·Frontiers in Oncology ·Hongyi Zhang, Xiaoyan Lin, Yu‐An Huang, Minghong Wang, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Yuan Wan, Fengfeng Cai	60
11	Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database 2020 ·BMC Cancer ·(unknown), (unknown), Chengjiao Zhang, Xiaoyan Lin, Ming Shan, (unknown), (unknown), (unknown), Hui Ye, Cheng Wang, (unknown)	9
12	FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer 2020 ·Cellular Oncology ·Chunli Yin, Xiaoyan Lin, (unknown), Xianqiang Liu, Yi Xiao, Jingchao Liu, Antoine M. Snijders, Guangwei Wei, Jian‐Hua Mao, Pengju Zhang	27
13	Hashimoto's Thyroiditis with Increased IgG4-Positive Plasma Cells: Using Thyroid-Specific Diagnostic Criteria May Identify Early Phase IgG4 Thyroiditis 2019 ·Thyroid ·Yaqiong Li, Xinli Wang, Zhiyan Liu, Jiwei Ma, Xiaoyan Lin, Yejun Qin, Eijun Nishihara, Akira Miyauchi, Kennichi Kakudo	17
14	Co-expression of parathyroid hormone related protein and TGF-beta in breast cancer predicts poor survival outcome 2015 ·BMC Cancer ·Cheng Xu, Zhengyuan Wang, Rongrong Cui, Hongyu He, Xiaoyan Lin, (unknown), Hongwei Zhang	16
15	Decreased HCRP1 expression is associated with poor prognosis in breast cancer patients. 2014 ·PubMed ·Jiawen Xu, (unknown), Qiangxiu Wang, Qinghui Zhang, (unknown), Xiaoyan Lin, Xiuping Liu, Yejun Qin	16
16	Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells 2013 ·Tumor Biology ·Fengfeng Cai, Isabell Ge, Minghong Wang, Ewelina Biskup, Xiaoyan Lin, Xiaoyan Zhong	14
17	A comparison of Twist and E-cadherin protein expression in primary non-small-cell lung carcinoma and corresponding metastases 2011 ·European Journal of Cardio-Thoracic Surgery ·Guanghui Wang, Wei Dong, Hongchang Shen, Xueru Mu, Zhenxiang Li, Xiaoyan Lin, Ying Liu, Jiajun Du	45
18	Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter 2007 ·Cancer Letters ·Peng Gao, Gengyin Zhou, Lingling Guo, Qinghui Zhang, Junhui Zhen, (unknown), Xiaoyan Lin	24
19	Alteration of Cyclin D1 in Chinese Patients with Breast Carcinoma and its Correlation with Ki-67, pRb, and p53 2007 ·Archives of Medical Research ·Lingling Guo, Peng Gao, (unknown), Wencheng Jian, Chunyan Hao, Hong Li, Xiaoyan Lin	16
20	Serum Levels of Endogenous Thrombopoietin and Granulocyte-Colony Stimulating Factor in Patients with Acute or Lymphoma Type Adult T-cell Leukemia During Multicycle Chemotherapy 2002 ·Leukemia & lymphoma ·Xiaoyan Lin, Shuichi Hanada, Kimiharu Uozumi, Atae Utsunomiya, Shinsuke Suzuki, (unknown), Shogo Takeuchi, Y Takatsuka, Terukatsu Arima	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact